References
- Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–42
- Santoro N, Sherman S. New Interventions for Menopausal Symptoms. Bethesda, MD: National Institutes of Health, US Dept of Health and Human Services, 2006
- MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
- North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355–69
- Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Climacteric 2014;17:557–63
- Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138–41
- Santoro N, Komi J. High prevalence and impact of vaginal symptoms among postmenopausal women. North American Menopause Society Meeting, Orlando, September 24–27, 2008, Abstract/Poster P-51
- Stenberg A, Heimer G, Ulmsten U, Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 1996;24:31–6
- Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–8
- Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas 2004;49:292–303
- Simon JA, Komi J. Postmenopausal women’s attitudes: Vulvovaginal atrophy and its symptoms. [NAMS Abstract LB-10]. Menopause 2007;14:1107
- Palma F, Volpe A, Villa P, Cagnacci A; as the Writing Group of the AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. Maturitas 2016;83:40–4
- Cagnacci A, Carbone MM, Palma F. Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study. Menopause 2016;23:1139–45
- Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric 2012;15:36–44
- Pfizer Pharmaceuticals, Inc. Healthy women survey. Available at: http://www.personalmenopauseanswers.com/healthywomen-survey.aspx. Accessed August 11, 2012
- Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10:1790–9
- Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013;10:2232–41
- Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. Am J Obstet Gynecol 2004;190:1272–7
- Capewell AE, McIntyre MA, Elton RA. Postmenopausal atrophy in elderly women: is a vaginal smear necessary for diagnosis. Age Ageing 1992;21:117–20
- Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and anthropic vaginitis. Am J Med Sci 1997;314:228–31
- Cano A, Estévez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study, Menopause 2012;19:1130–9
- Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9
- Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Women’s Health (Larchmt) 2010;19:425–32
- Brown KH, Hammond CB. Urogenital atrophy. Obstet Gynecol Clin North Am 1987;14:13–32
- Semmens JP, Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA 1982;248:445–8
- Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE Survey. Clin Med Insights Reprod Health 2014;8:23–30
- Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Women’s Health 2013;5:437–47
- Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010;67:233–8
- Sobecki JN, Curlin FA, Rasinski KA, Lindau ST. What we don’t talk about when we don’t talk about sex: results of a national survey of US obstetrician/gynecologists. J Sex Med 2012;9:1285–94
- Nappi RE, Particco M, Biglia N, et al. Attitude and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: evidence from the European REVIVE survey. Maturitas 2016;91:74–80
- Palacios S, Mejía A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric 2015;18(Suppl 1):23–9
- North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
- Nappi R, Palacios S, Panay N, Rabe T, Ktychman M, Particco M. Results of the European REVIVE (REal Women’s VIew of Treatment Options for Menopausal Vulvar/Vaginal ChangEs) survey. Maturitas 2015;81:144–90
- Bachmann GA, Leiblum SR, Grill J. Brief sexual inquiry in gynecologic practice. Obstet Gynecol 1989;73:425–7
- Theroux R. Women’s decision making during the menopausal transition. J Am Acad Nurse Pract 2010;22:612–21
- Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22